Likelihood of Null Effects of Large NHLBI Clinical Trials Has Increased over Time
PLoS ONEPublished 5 August 2015Open access
Robert M. Kaplan, Veronica L. Irvin
Citations372
SJR quartileQ1
SJR score0.80
SNIP1.07
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The number NHLBI trials reporting positive results declined after the year 2000, and the adoption of transparent reporting standards, as required by clinicaltrials.gov, may have contributed to the trend toward null findings.
Abstract
The number NHLBI trials reporting positive results declined after the year 2000. Prospective declaration of outcomes in RCTs, and the adoption of transparent reporting standards, as required by clinicaltrials.gov, may have contributed to the trend toward null findings.
Keywords
Decision SciencesMathematicsEconomics, Econometrics and Finance
The LancetPublication bias in clinical research
3,095 Citations1991Philippa Easterbrook, Radha Gopalan +2 more
The presence of publication bias in a cohort of clinical research studies is confirmed and it is suggested that conclusions based only on a review of published data should be interpreted cautiously, especially for observational studies.
JAMAThe CONSORT Statement: Revised Recommendations for Improving the Quality of Reports of Parallel-Group Randomized Trials
2,530 Citations2001David Moher
The revised CONSORT statement presented in this paper incorporates new evidence and addresses some criticisms of the original statement to improve the reporting of an RCT, enabling readers to understand a trial's conduct and to assess the validity of its results.
Alzheimer s Research & TherapyAlzheimer’s disease drug-development pipeline: few candidates, frequent failures
1,744 Citations2014Jeffrey L. Cummings, Travis Morstorf +1 more
The Clinicaltrials.gov database demonstrates that relatively few clinical trials are undertaken for AD therapeutics, considering the magnitude of the problem, and the success rate for advancing from one phase to another is low and the number of compounds progressing to regulatory review is among the lowest found in any therapeutic area.
New England Journal of MedicineThe ClinicalTrials.gov Results Database — Update and Key Issues
789 Citations2011Deborah A. Zarin, Tony Tse +3 more
The structure and contents of the results database are summarized, an update of relevant policies are provided, and how the data can be used to gain insight into the state of clinical research are shown.
New England Journal of MedicineTrial Registration at ClinicalTrials.gov between May and October 2005
295 Citations2005Deborah A. Zarin, Tony Tse +1 more
Overall, the data contained in records were more complete in October than they were in May, but there still is room for substantial improvement.
Journal of the American College of CardiologyCardiovascular Drug Development
204 Citations2015Christopher B. Fordyce, Matthew T. Roe +19 more
The current adverse trends in cardiovascular drug development are delineated, the key issues that underlie these trends are understood within the context of a recognized need for a rigorous regulatory review process, and potential solutions to the problems identified are provided.
ScienceMoving Toward Transparency of Clinical Trials
182 Citations2008Deborah A. Zarin, Tony Tse
As new policies promote transparency of clinical trials through registries and results databases, further issues arise and require examination.
New England Journal of MedicinePublication of Trials Funded by the National Heart, Lung, and Blood Institute
111 Citations2013David Gordon, Wendy C. Taddei‐Peters +4 more
Results of less than two thirds of NHLBI-funded randomized clinical trials of cardiovascular interventions were published within 30 months after completion of the trial, while trials that focused on clinical events were published more quickly than those thatfocused on surrogate end points.
Social Science & MedicinePeering into the pharmaceutical “pipeline”: Investigational drugs, clinical trials, and industry priorities
63 Citations2014Jill A. Fisher, Marci D. Cottingham +1 more
Annals of Internal MedicineEconomic Return From the Women's Health Initiative Estrogen Plus Progestin Clinical Trial
58 Citations2014Joshua A. Roth, Ruth Etzioni +9 more
A disease-simulation model was developed to evaluate clinical and economic outcomes for cHT-eligible women since the initial publication of the E+P trial results and compared disease incidence, survival, health-related quality of life, and direct medical expenditure outcomes for WHI versus no-WHI scenarios.
Clinical and Translational ScienceTracking the Pharmaceutical Pipeline: Clinical Trials and Global Disease Burden
9 Citations2014Marci D. Cottingham, Corey A. Kalbaugh +1 more
The pharmaceutical pipeline is tracked using data from industry publications that provide otherwise unreported information about industry‐sponsored clinical trials to suggest that pharmaceutical development does not adequately address global disease burden.